Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 23 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a partnership with Bioeq for the U.S. commercialization rights of NUFYMCO®, a biosimilar to Lucentis®, which has received approval from the USFDA. Under this agreement, Bioeq will handle development and manufacturing, while Zydus will focus on commercialization in the U.S. market. This collaboration aims to enhance access to affordable ophthalmology care for patients in the U.S.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO®. BLA has been approved by the USFDA".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases